Mastocytosis in the Pediatric Patient

Mastocytosis is a group of hematopoietic disorders characterized by an abnormal increase and growth of mast cells (MCs) in the body’s tissues. The World Health Organization (WHO) classifies mastocytosis into cutaneous mastocytosis (CM) and systemic mastocytosis (SM), with different variants of SM further distinguished. CM primarily affects the skin, while SM involves organs such as the bone marrow and liver. Diagnosis of mastocytosis relies on specific features and criteria for different forms, and the International Classification of Diseases-10-Clinical Modification (ICD-10-CM) provides relevant codes for accurate diagnosis. Serum tryptase levels can be elevated in monomorphic mast cell proliferative disorders (MPCM) and diffuse cutaneous mastocytosis (DCM) but not necessarily in polymorphic MPCM and mastocytomas. In most cases, a skin biopsy is not required for mastocytoma diagnosis unless there is uncertainty. Mastocytosis is associated with somatic gain-of-function mutations in the KIT gene, with the D816V mutation being the most common in both pediatric and adult cases. However, pediatric cutaneous mastocytosis can exhibit diverse KIT mutations. An elevated serum tryptase level (>20 ng/ml), along with abnormalities in blood tests and organ enlargement, can indicate systemic mastocytosis. It is crucial to consider hereditary alpha-tryptasemia (HAT) in the differential diagnosis. Therapeutic interventions for mastocytosis focus on managing specific symptoms and preventing triggers. The treatment approach aims to improve the quality of life for individuals with mastocytosis by controlling symptoms such as itching, flushing, and gastrointestinal issues. Close monitoring and collaboration between patients and healthcare providers are essential for optimal management of the condition.